AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34763441 — intervention group
Group type: COMPARATOR
Intervention: Gravity drip administration of contrast media (O group, n=50)
Number of subjects: 100
Study 35862342 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) with varying parameters (stimulating site, frequency, intensity, pulse number)
Number of subjects: 45
Study 33217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 154
Study 33217054 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 154
Study 35366928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ludangshen oral liquid
Number of subjects: 200
Study 35366928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34363470 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional venous reservoir for CO2 drainage
Number of subjects: 10
Study 34363470 — intervention group
Group type: COMPARATOR
Intervention: Standard venous reservoir without additional CO2 drainage
Number of subjects: 10
Study 32171078 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus mefloquine
Number of subjects: 1100
Study 32171078 — intervention group
Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 1100
Study 32171078 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 1100
Study 32171078 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine plus amodiaquine
Number of subjects: 1100
Study 32171078 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 1100
Study 35608396 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD bundle (pain monitoring and management, light sedation and daily awakening, early mobility, sleep promotion, and delirium monitoring)
Number of subjects: 243
Study 35608396 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 243
Study 35608396 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD bundle
Number of subjects: 243
Study 34280355 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib 125 mg thrice daily for 2 years
Number of subjects: 322
Study 34280355 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (vinorelbine and cisplatin or pemetrexed and cisplatin)
Number of subjects: 322
Study 34280355 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 322
Study 34280355 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 322
Study 33262576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 74
Study 33262576 — intervention group
Group type: COMPARATOR
Intervention: Control (group N)
Number of subjects: 74
Study 32852646 — intervention group
Group type: EXPERIMENTAL
Intervention: Te‐PTK with MMC 0.02%
Number of subjects: 63
Study 32852646 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.03% ointment applied once daily for 2–6 months
Number of subjects: 63
Study 32852646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 32078926 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat app-based education and rehabilitation program (WERP)
Number of subjects: 200
Study 33933667 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIT intervention (cognitive behavioral therapy-based, individual weekly counseling sessions targeting anxiety and depressive symptoms)
Number of subjects: 180
Study 33933667 — intervention group
Group type: COMPARATOR
Intervention: Time-Matched Control (TMC) (cognitive behavioral therapy-based, individual weekly counseling sessions)
Number of subjects: 180
Study 33933667 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 180
Study 33237140 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 20
Study 33237140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 36293716 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellbeing Training based on Contemplative Practices (WTCP)
Number of subjects: 38
Study 36293716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 33878107 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 120
Study 33878107 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 120
Study 33878107 — intervention group
Group type: COMPARATOR
Intervention: Control (PE class)
Number of subjects: 120
Study 34371005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modifications (handrails for outside steps and internal stairs, grab rails for bathrooms, outside lighting, repairs to window catches, high-visibility and slip-resistant edging for outside steps, fixing of lifted edges of carpets and mats, non-slip bath mats, slip-resistant surfacing for outside areas such as decks)
Number of subjects: 254
Study 34371005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no modifications for 3 years)
Number of subjects: 254
Study 32053547 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop RT assessment
Number of subjects: 41
Study 32053547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task assessments
Number of subjects: 41
Study 32053547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg hop
Number of subjects: 41
Study 32053547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task assessments
Number of subjects: 41
Study 36116485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potential naphthoquinones (2-chloro-, 2-bromo-, 2,3-dichloro-, and 2,3-dibromo-1,4-naphthoquinone) incorporated into the A1 binding site
Number of subjects: 4
Study 36116485 — intervention group
Group type: COMPARATOR
Intervention: Native photosystem I with phylloquinone in the A1 binding site
Number of subjects: 4
Study 34435610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercession prayer applied three times during hemodialysis sessions.
Number of subjects: 62
Study 34435610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prayer intervention).
Number of subjects: 62
Study 34435610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with prayer intervention).
Number of subjects: 62
Study 32074412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics treatment
Number of subjects: 421
Study 32669052 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-inertial flywheel training (FW)
Number of subjects: 18
Study 32669052 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic resistance training (PN)
Number of subjects: 18
Study 32410099 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Approach to Autism Programming for Schools (MAAPS)
Number of subjects: 0
Study 36333896 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day) for 14 days
Number of subjects: 65
Study 36333896 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (15 mg/kg/day) for 28 days
Number of subjects: 65
Study 33585378 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Micronutrient Fortified Body Oil (LMF)
Number of subjects: 0
Study 33585378 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35215466 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (AM)
Number of subjects: 33
Study 35215466 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (PM)
Number of subjects: 33
Study 33275913 — intervention group
Group type: EXPERIMENTAL
Intervention: Optivista (OV) IEE
Number of subjects: 410
Study 33275913 — intervention group
Group type: COMPARATOR
Intervention: iScan (IS) IEE
Number of subjects: 410
Study 35297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised outdoors exercise program followed by a 6-month maintenance phase
Number of subjects: 80
Study 33285733 — intervention group
Group type: EXPERIMENTAL
Intervention: Danlou tablet (1.5 mg a time, 3 times daily for 28 days)
Number of subjects: 76
Study 33285733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35514063 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral with navigation intervention (n = 995)
Number of subjects: 1554
Study 35514063 — intervention group
Group type: COMPARATOR
Intervention: Referral only (n = 559)
Number of subjects: 1554
Study 33856157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Socket (DS)
Number of subjects: 13
Study 33856157 — intervention group
Group type: COMPARATOR
Intervention: Ischial Ramus Containment (IRC)
Number of subjects: 13
Study 33856157 — intervention group
Group type: EXPERIMENTAL
Intervention: Subischial (Sub-I)
Number of subjects: 13
Study 33856157 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-study preference
Number of subjects: 13
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia psittaci detected in blue-fronted Amazon parrots
Number of subjects: 212
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroscopic changes observed
Number of subjects: 212
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic lesions observed
Number of subjects: 212
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Stained tissue sections (Gimenez technique)
Number of subjects: 212
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analyses of ompA gene sequences
Number of subjects: 212
Study 32286573 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations based on findings
Number of subjects: 212
Study 35490461 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation for 17 days
Number of subjects: 50
Study 35490461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35275249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 53
Study 35275249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 36181541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 117
Study 36181541 — intervention group
Group type: COMPARATOR
Intervention: Clinical prediction model
Number of subjects: 117
Study 36181541 — intervention group
Group type: COMPARATOR
Intervention: Individual radiologic characteristic model
Number of subjects: 117
Study 34378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg
Number of subjects: 2199
Study 34378456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study 34343295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-atrial (BA) lesion
Number of subjects: 80
Study 34343295 — intervention group
Group type: COMPARATOR
Intervention: Box lesion
Number of subjects: 80
Study 32630214 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training during Christmas (TRAIN group)
Number of subjects: 38
Study 32630214 — intervention group
Group type: COMPARATOR
Intervention: Discontinued training during Christmas (HOLID group)
Number of subjects: 38
Study 34961754 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention during chemotherapy (n = 173)
Number of subjects: 419
Study 34961754 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (n = 172)
Number of subjects: 419
Study 34961754 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (n = 419)
Number of subjects: 419
Study 33715265 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset dysferlinopathy patients
Number of subjects: 48
Study 33715265 — intervention group
Group type: COMPARATOR
Intervention: Early-onset dysferlinopathy patients (control group)
Number of subjects: 48
Study 32808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse additive model for treatment effect modification
Number of subjects: 0
Study 32808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation experiments
Number of subjects: 0
Study 32808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Application to a dataset from a randomized clinical trial
Number of subjects: 0
Study 34572935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 372
Study 34572935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 36434957 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodform intervention (n = 244)
Number of subjects: 488
Study 36434957 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 244)
Number of subjects: 488
Study 32697104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient psychosocial treatment (18-week cognitive-behavioral treatment, two 90-min sessions per week)
Number of subjects: 88
Study 32697104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient psychosocial treatment
Number of subjects: 88
Study 32697104 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 88
Study 33023920 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 2925
Study 32223354 — intervention group
Group type: EXPERIMENTAL
Intervention: TCC‐EZ
Number of subjects: 15
Study 32462746 — intervention group
Group type: EXPERIMENTAL
Intervention: 0–2 days of sexual abstinence (group 1)
Number of subjects: 90
Study 32462746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3–4 days of sexual abstinence (group 2)
Number of subjects: 90
Study 32462746 — intervention group
Group type: EXPERIMENTAL
Intervention: >4 days of sexual abstinence (group 3)
Number of subjects: 90
Study 35286322 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus rifaximin
Number of subjects: 32
Study 35286322 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 32
Study 33939512 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-only treatment
Number of subjects: 0
Study 33939512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-plus-email treatment
Number of subjects: 0
Study 33939512 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumers who switched out of a plan chosen in error
Number of subjects: 0
Study 36209240 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) administered via telephone
Number of subjects: 0
Study 36209240 — intervention group
Group type: COMPARATOR
Intervention: In-person Montreal Cognitive Assessment (MoCA)
Number of subjects: 0
Study 34816747 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐step RX‐MC‐Monoblock
Number of subjects: 60
Study 34816747 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐step Monoblock MC
Number of subjects: 60
Study 34816747 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐step RX‐MC
Number of subjects: 60
Study 34816747 — intervention group
Group type: COMPARATOR
Intervention: Monoblock MC‐NA (no adhesive)‐GFP
Number of subjects: 60
Study 32111233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based resilience training
Number of subjects: 0
Study 32111233 — intervention group
Group type: COMPARATOR
Intervention: Attention control (stress management education)
Number of subjects: 0
Study 32111233 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 36233454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient fentanyl (maximum estimated effect site concentration: 7.86 ng/mL)
Number of subjects: 30
Study 36233454 — intervention group
Group type: COMPARATOR
Intervention: Minimum fentanyl (maximum estimated effect site concentration: 1.5 ng/mL)
Number of subjects: 30
Study 35134703 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet‐based self‐help problem solving therapy intervention
Number of subjects: 190
Study 35134703 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 190
Study 34246457 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic molecule for nausea and vomiting prevention during chemotherapy
Number of subjects: 0
Study 34246457 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 36302537 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for 6 days and 0.5 mg q.d. for the second week)
Number of subjects: 96
Study 36302537 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 96
Study 36302537 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 96
Study 36302537 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 36302537 — intervention group
Group type: COMPARATOR
Intervention: Colchicine and Control
Number of subjects: 96
Study 32641154 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg orally once daily (OD) on days 1‐14 or until discharge; reduced to 2 mg OD for patients aged >75 years or with creatinine clearance of 30‐60 ml/min.
Number of subjects: 375
Study 32641154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab administered intravenously once according to licensed weight‐based dosing regimen.
Number of subjects: 375
Study 32641154 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone.
Number of subjects: 375
Study 35881983 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote protocol for diabetes prevention intervention
Number of subjects: 99
Study 35881983 — intervention group
Group type: COMPARATOR
Intervention: In-person protocol for diabetes prevention intervention
Number of subjects: 99
Study 32689752 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV combined with HFNCO
Number of subjects: 73
Study 32689752 — intervention group
Group type: COMPARATOR
Intervention: NIV alone
Number of subjects: 73
Study 35619152 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 10000
Study 35619152 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone game follow-up
Number of subjects: 10000
Study 35619152 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-person follow-up
Number of subjects: 10000
Study 32791592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline lavage
Number of subjects: 20
Study 32791592 — intervention group
Group type: COMPARATOR
Intervention: Normal saline lavage
Number of subjects: 20
Study 35400605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dystocia Line partograph (n = 114)
Number of subjects: 228
Study 35400605 — intervention group
Group type: COMPARATOR
Intervention: Action Line partograph (n = 114)
Number of subjects: 228
Study 33705671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HPS) training
Number of subjects: 50
Study 33705671 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 50
Study 35803552 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone (Control)
Number of subjects: 381
Study 32165251 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 5-10 mg
Number of subjects: 76
Study 32165251 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 1.5-3.0 mg
Number of subjects: 76
Study 32165251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 34364165 — intervention group
Group type: EXPERIMENTAL
Intervention: WEKA image analysis tool
Number of subjects: 12
Study 34364165 — intervention group
Group type: COMPARATOR
Intervention: Colour Deconvolution, SpotStudio, WEKA, LEICA RNA‐ISH algorithm
Number of subjects: 12
Study 35365239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DW-MSC (5.0×10^7 cells)
Number of subjects: 9
Study 35365239 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DW-MSC (1.0×10^8 cells)
Number of subjects: 9
Study 35365239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 9
Study 35365239 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TL, TH, C)
Number of subjects: 9
Study 35946280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (400 μg daily for 12 weeks)
Number of subjects: 48
Study 34324536 — intervention group
Group type: EXPERIMENTAL
Intervention: High scoring organizations on social value
Number of subjects: 400
Study 34324536 — intervention group
Group type: EXPERIMENTAL
Intervention: High scoring organizations on environmental value
Number of subjects: 400
Study 34324536 — intervention group
Group type: EXPERIMENTAL
Intervention: High scoring organizations on application value
Number of subjects: 400
Study 34324536 — intervention group
Group type: COMPARATOR
Intervention: Low scoring organizations on social value
Number of subjects: 400
Study 34324536 — intervention group
Group type: COMPARATOR
Intervention: Low scoring organizations on environmental value
Number of subjects: 400
Study 34324536 — intervention group
Group type: COMPARATOR
Intervention: Low scoring organizations on application value
Number of subjects: 400
Study 34907435 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 342
Study 34907435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g three times daily)
Number of subjects: 342
Study 34907435 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 342
Study 34135506 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 581
Study 34135506 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581
Study 35038407 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music intervention
Number of subjects: 976
Study 34346159 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday allied health service events
Number of subjects: 243549
Study 34346159 — intervention group
Group type: COMPARATOR
Intervention: Weekend allied health service events
Number of subjects: 243549
Study 32972733 — intervention group
Group type: EXPERIMENTAL
Intervention: OS‐IUI treatment cycles
Number of subjects: 868
Study 32709173 — intervention group
Group type: EXPERIMENTAL
Intervention: Kambin triangle approach (KB group; n = 37)
Number of subjects: 75
Study 32709173 — intervention group
Group type: COMPARATOR
Intervention: Subpedicular approach (SP group; n = 38)
Number of subjects: 75
Study 35786815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivity group
Number of subjects: 88
Study 35786815 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofocal group
Number of subjects: 88
Study 35786815 — intervention group
Group type: EXPERIMENTAL
Intervention: AT Lara group
Number of subjects: 88